Dr. Benjamin Haibe-Kains
Dr. Haibe-Kains’ research focuses on the integration of high-throughput data from various sources to simultaneously analyze multiple facets of carcinogenesis. He and his team are analyzing high-throughput pharmacogenomic datasets to develop new prognostic and predictive models and to discover new therapeutic regimens to improve disease management. Haibe-Kains’ main scientific contributions include several prognostic gene signatures in breast cancer, subtype classification models for ovarian and breast cancers, as well as genomic predictors of drug response in cancer cell lines.
- Associate, OICR
- Senior Scientist, Princess Margaret Cancer Centre
- Associate Professor, Department of Medical Biophysics, University of Toronto
- Adjunct Assistant Professor, Department of Computer Science, University of Toronto
- Affiliate, Vector Institute
- Computational biology
- Machine learning
- Haibe-Kains B, El-Hachem N, Birkbak NJ, …, Quackenbush J. Inconsistency in large pharmacogenomic studies. Nature. 2013;504(7480):389-93.
- Smirnov P, Kofia V, Maru A, …, Haibe-Kains B. PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies. Nucleic Acids Res. 2018;46(D1):D994-D1002.
- Safikhani Z, Smirnov P, Thu KL, …, Haibe-Kains B. Gene isoforms as expression-based biomarkers predictive of drug response in vitro. Nat Commun. 2018;9(1):166.
- El-Hachem N, Gendoo DM, Soltan Ghoraie L, …, Haibe-Kains B. Integrative cancer pharmacogenomics to infer large-scale drug taxonomy. Cancer Res. 2017;77(11):3057-3069.
- Aerts HJ, Velazquez ER, Leijenaar RT, …, Haibe-Kains B, …, Lambin P. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
- CrosstalkNet: a web-application focused on exploring the interactions between tumor epithelial and stromal cells in a bipartite graph
- PharmacoDB: a web-application and database enabling efficient mining of a compendium of large pharmacogenomic studies where panels of immortalized cancer cell lines have been screened against hundreds of approved and experimental drug compounds
More of Dr. Haibe-Kains’ tools can be found on his laboratory page.
- Biomarkers for TTK Inhibition, US62/675228, 2018.
- Methods and tools for prognosis of cancer in HER2+ patients, WO 2010/118782, 2009.
- Methods and tools for prognosis of cancer in ER- patients, US 2010/0298160, 2009.
- Method and kit for the detection of genes associated with PIK3CA mutation and involved in PI3K/AKT pathway activation in the ERpositive and HER2 positive subtypes with clinical implications, WO 2009/103790, 2009.
- Canadian Institutes of Health Research – Institute of cancer Research, Canadian Cancer Society, Ontario Institute for Cancer Research, Early Career Researcher Program Award, 2017
- Canadian Institutes of Health Research, New Investigator Award, 2015
- Ministry of Economic Development and Innovation/Ministry of Research & Innovation in Ontario, Early Researcher Award, 2015
- Canadian Cancer Society Research Institute, Junior Investigator Grant Panel Travel Award, 2014
- Committee of the Translational Bioinformatics Conference, Travel Grant, 2012
- National Cancer Institute, Travel Grant, 2011
- European Society for Medical Oncology, Travel Grant, 2010
- Solvay Institutes, Solvay Awards for doctoral research, 2010
- PhD, Computer Science, Université Libre de Bruxelles
- Master’s degree, Advanced Studies in Science, Université Libre de Bruxelles
- Master’s degree, Bioinformatics, Université Libre de Bruxelles
- BSc, Computer Science, Université Libre de Bruxelles
Opportunities to collaborate
For opportunities to collaborate with Dr. Haibe-Kains, please contact him directly.
Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.